Immunovia AB has completed a private placement of shares through an accelerated book-building procedure performed by Kempen & Co, Danske Bank and Vator Securities, providing the company with proceeds of approximately SEK 400 million before transaction related costs.

Immunovia is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™.

A large number of Swedish and international institutional investors participated in the transaction. The proceeds from the transaction will be used to finance Immunovia’s investments in an accelerated commercialization start for IMMray™ PanCan-d and for general corporate purposes.

Baker McKenzie acted as legal advisor to Immunovia in connection with the transaction. Kempen & Co and Danske Bank acted as Joint Global Coordinators and Joint Bookrunners and Vator Securities was Joint Bookrunner.

Baker McKenzie’s team consisted of Joakim Falkner, Henric Roth and Ian Gulam from Baker McKenzie's Stockholm office and of Megan Schellinger from the London office.
Explore Our Newsroom